A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 20 Jun 2018 Planned End Date changed from 22 Dec 2018 to 7 Mar 2019.
- 22 Mar 2018 Planned primary completion date changed from 10 Sep 2018 to 22 Nov 2018.
- 23 Feb 2018 Planned End Date changed from 10 Oct 2018 to 22 Dec 2018.